EGFR and ovarian carcinoma: As we learn more about the complexities of specific signaling changes associated with EGFR mutation and overexpression, future studies using EGFR antagonists in ovarian cancer should focus on determining reliable predictors for patient responsiveness to anti-EGFR therapy such as by obtaining good biomarker profiles and utilizing assays most appropriate to determine EGFR status as well as developing rational combination therapies with EGFR inhibitors.